Last reviewed · How we verify
tocilizumab or sarilumab (tocilizumab-or-sarilumab)
Tocilizumab or sarilumab, developed by Pfizer Inc., is a marketed drug with a mechanism of action that targets the interleukin-6 receptor. It is primarily used to treat Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and other conditions. The drug's clinical differentiation lies in its ability to reduce inflammation and prevent joint damage. Commercially, it has generated significant revenue of 63.6 billion. The pipeline developments for this drug are not specified. Overall, tocilizumab or sarilumab is a key treatment option for patients with these conditions.
At a glance
| Generic name | tocilizumab-or-sarilumab |
|---|---|
| Sponsor | Pfizer |
| Drug class | monoclonal antibody |
| Target | interleukin-6 receptor |
| Modality | Monoclonal antibody |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| Annual revenue | 116 |
Approved indications
- Rheumatoid Arthritis
- Juvenile Idiopathic Arthritis
- Polyarticular Juvenile Idiopathic Arthritis
- Megakaryocyte Erythroid Potent Protocadherin-related Protein (MEPEP) associated Hemophagocytic Lymphohistiocytosis
- Cytokine Release Syndrome
- Giant Cell Arteritis
- Polyarticular Juvenile Idiopathic Arthritis
- Systemic Juvenile Idiopathic Arthritis
- Systemic Sclerosis
- COVID-19
- Cytokine Release Syndrome
- Giant Cell Arteritis
- Polyarticular Juvenile Idiopathic Arthritis
- Systemic Juvenile Idiopathic Arthritis
- Systemic Sclerosis
- COVID-19
- Cytokine Release Syndrome
- Giant Cell Arteritis
- Polyarticular Juvenile Idiopathic Arthritis
- Systemic Juvenile Idiopathic Arthritis
Common side effects
Drug interactions
- Tocilizumab
- Tocilizumab
- Tocilizumab
- Tocilizumab
- Tocilizumab
- Tocilizumab
- Tocilizumab
- Sarilumab
- Sarilumab
- Sarilumab
- Sarilumab
- Sarilumab
Key clinical trials
- Stand UP to Rheumatoid Arthritis (SUPRA) (NA)
- Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers (PHASE1, PHASE2)
- A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis
- RA-PRO PRAGMATIC TRIAL (PHASE3)
- Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide (PHASE4)
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
- Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- tocilizumab or sarilumab CI brief — competitive landscape report
- tocilizumab or sarilumab updates RSS · CI watch RSS
- Pfizer portfolio CI